Dual Orexin Receptor Antagonists for Chronic Insomnia

When to Initiate After Non-Pharmacologic Failure

Dual orexin receptor antagonists (DORAs) should be started immediately after documented failure of cognitive-behavioral therapy for insomnia (CBT-I) or when CBT-I is unavailable, as they represent first-line pharmacologic options with superior safety profiles compared to traditional hypnotics. 1, 2, 3

The American Academy of Sleep Medicine (2017) recommends suvorexant for sleep-maintenance insomnia when non-pharmacologic measures prove insufficient, establishing DORAs as evidence-based alternatives to benzodiazepine receptor agonists. 1
DORAs preserve natural sleep architecture, lack physiological tolerance, produce no withdrawal symptoms upon abrupt discontinuation, and carry minimal abuse potential—advantages that position them ahead of GABAergic hypnotics in the treatment algorithm. 4, 5

Agent Selection Based on Sleep Complaint

Sleep-Maintenance Insomnia (Frequent Awakenings, Early-Morning Awakening)

Lemborexant 5 mg is the preferred initial choice because it demonstrates the greatest reduction in wake after sleep onset (WASO) among all DORAs (mean difference -45.15 minutes vs. placebo) while maintaining excellent tolerability at this dose. 6, 5
Daridorexant 25–50 mg is an alternative when lemborexant is unavailable or not tolerated; the 50 mg dose shows sustained efficacy over 12 months without new safety signals. 7, 8
Suvorexant 10–20 mg (15 mg in adults ≥65 years) remains effective but shows smaller effect sizes for sleep maintenance compared to lemborexant and daridorexant. 1, 4

Sleep-Onset Insomnia (Difficulty Falling Asleep)

Lemborexant 10 mg produces the largest reduction in subjective sleep-onset latency (standardized mean difference -0.430) among DORAs and is superior to suvorexant for initiating sleep after 1 week of treatment. 4, 5
Daridorexant 50 mg is a second-line option for sleep onset, though its effect size is smaller than lemborexant 10 mg. 4
Suvorexant shows the smallest effect on sleep-onset latency (standardized mean difference -0.164) and should be reserved for patients who fail other DORAs. 4

Combined Sleep-Onset and Sleep-Maintenance Insomnia

Lemborexant 10 mg addresses both domains effectively and should be the first choice. 6, 5
Daridorexant 50 mg is an alternative when lemborexant is contraindicated or unavailable. 7, 8

Recommended Initial Doses and Titration

Suvorexant (Belsomra)

Initial dose: 10 mg taken within 30 minutes of bedtime with at least 7 hours remaining before planned awakening. 1
Titration: If 10 mg is insufficient after 1–2 weeks, increase to 20 mg (or 15 mg in adults ≥65 years). 1, 9
Maximum dose: 20 mg (15 mg in older adults). 9
Avoid taking with or soon after meals, as food delays absorption and reduces efficacy. 9

Lemborexant (Dayvigo)

Initial dose: 5 mg for sleep-maintenance insomnia or when minimizing daytime somnolence is a priority. 10, 5
Titration: If 5 mg is insufficient after 1–2 weeks, increase to 10 mg for sleep-onset insomnia or combined complaints. 5, 6
Maximum dose: 10 mg. 10
The 5 mg dose is similarly well tolerated as placebo, while the 10 mg dose carries a higher risk of next-day somnolence (RR 5.62). 6

Daridorexant (Quviviq)

Initial dose: 25 mg for most patients, taken within 30 minutes of bedtime with at least 7 hours remaining before planned awakening. 7
Titration: If 25 mg is insufficient after 1–2 weeks, increase to 50 mg; the 50 mg dose demonstrates dose-dependent superiority in all efficacy outcomes. 7, 4
Maximum dose: 50 mg. 7
Time to sleep onset is delayed if taken with or soon after a meal. 7

Safety Considerations and Contraindications

Absolute Contraindications

Narcolepsy is an absolute contraindication to all DORAs because orexin deficiency is the pathophysiologic basis of narcolepsy. 7
History of hypersensitivity to the specific DORA or any component; angioedema with pharyngeal involvement has been reported with daridorexant. 7

CNS-Depressant Effects and Next-Day Impairment

All DORAs can impair daytime wakefulness even when used as prescribed; CNS-depressant effects may persist for several days after discontinuation. 7
Driving impairment was documented in some subjects taking daridorexant 50 mg; patients must be counseled to avoid driving and activities requiring complete mental alertness if they take the medication with less than 7 hours of sleep remaining or at higher-than-recommended doses. 7
Lemborexant 10 mg carries the highest risk of next-day somnolence (RR 5.62 vs. placebo), while lemborexant 5 mg and daridorexant 25 mg show minimal somnolence risk. 6, 4

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): Avoid concomitant use with daridorexant; if unavoidable, reduce daridorexant to 25 mg. 7
Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, grapefruit juice): Reduce daridorexant to 25 mg. 7
Strong or moderate CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort): Avoid concomitant use with daridorexant, as efficacy will be markedly reduced. 7
Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, alcohol) increases the risk of respiratory depression and profound sedation; avoid combining multiple sedative-hypnotics. 7

Hepatic Impairment

Moderate hepatic impairment (Child-Pugh score 7–9): Maximum dose of daridorexant is 25 mg. 7
Severe hepatic impairment (Child-Pugh score ≥10): Daridorexant is not recommended. 7
Lemborexant and suvorexant dosing adjustments in hepatic impairment are not well defined in the evidence provided; consult FDA labeling.

Special Populations

Older adults (≥65 years): Use lower doses (suvorexant 15 mg instead of 20 mg; daridorexant 25 mg initially) due to slower drug clearance and higher risk of falls and cognitive impairment. 7, 9
Women: FDA advises dose reductions for most hypnotics due to slower metabolism; start with the lowest effective dose. 2
Patients with substance-use disorder: DORAs are preferred over benzodiazepines and Z-drugs because they lack abuse potential and do not produce physiological dependence. 3, 4

Observational Safety Data

Observational studies link hypnotic use to increased risks of dementia (RR 2.34), fractures, and major injuries, though these data primarily reflect benzodiazepine and Z-drug use rather than DORAs. 2, 3
DORAs exhibit lower abuse potential and fewer cognitive side effects compared to GABAergic hypnotics, supporting their preferential use in at-risk populations. 3, 4

Common Pitfalls and How to Avoid Them

Prescribing DORAs with insufficient sleep opportunity: Patients must have at least 7 hours remaining before planned awakening to minimize next-day impairment; counsel patients explicitly on this requirement. 7
Taking DORAs with or after meals: Food delays absorption and reduces efficacy; instruct patients to take the medication on an empty stomach or at least 2 hours after eating. 7, 9
Combining multiple sedative-hypnotics: This practice markedly raises the risk of respiratory depression and other serious adverse events without evidence of added benefit; avoid polypharmacy. 7
Continuing ineffective therapy beyond 2–4 weeks: Reassess the diagnosis and consider alternative agents or non-pharmacologic interventions if no improvement occurs within this timeframe. 2
Using DORAs in patients with narcolepsy: This is an absolute contraindication and will worsen excessive daytime sleepiness. 7
Ignoring CYP3A4 interactions: Failure to adjust doses or avoid concomitant use of strong inhibitors/inducers can lead to toxicity or treatment failure. 7

Duration of Therapy

Acute treatment (4–12 weeks): All DORAs have robust efficacy data supporting short-term use. 1, 2
Long-term treatment (>12 weeks): Daridorexant 50 mg has been studied for up to 12 months and maintains efficacy without new safety signals, withdrawal symptoms, or rebound insomnia upon discontinuation. 8
DORAs do not require tapering when discontinued, unlike benzodiazepines and Z-drugs, simplifying deprescribing. 4, 8

Clinical Decision Algorithm

Confirm chronic insomnia diagnosis and document failure of non-pharmacologic measures (CBT-I or equivalent). 1, 2
Identify the predominant sleep complaint:
- Sleep-maintenance insomnia → Start lemborexant 5 mg. 5, 6
- Sleep-onset insomnia → Start lemborexant 10 mg. 5, 6
- Combined onset and maintenance → Start lemborexant 10 mg. 5, 6
Screen for contraindications: Narcolepsy, hypersensitivity, severe hepatic impairment. 7
Assess drug interactions: Adjust dose or avoid DORAs if strong/moderate CYP3A4 inhibitors or inducers are present. 7
Counsel on administration: Take within 30 minutes of bedtime, with at least 7 hours of sleep opportunity, on an empty stomach. 7, 9
Reassess after 1–2 weeks: If insufficient response, titrate to the next higher dose (lemborexant 5 mg → 10 mg; daridorexant 25 mg → 50 mg; suvorexant 10 mg → 20 mg). 7, 5, 9
Monitor for adverse events: Somnolence, dizziness, headache, abnormal dreams; discontinue if severe or intolerable. 4, 11, 6
Plan for long-term use: DORAs can be continued beyond 12 weeks without concerns for tolerance, withdrawal, or rebound insomnia. 8

When should dual orexin receptor antagonists be started in an adult with chronic insomnia after non‑pharmacologic measures have failed, and what are the recommended initial doses and safety considerations for suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq)?

Have a follow-up question?